Loss of Control of HIV Viremia With OTC Weight-Loss Drugs: A Call for Caution?
Dario CattaneoAndrea GiacomelliCristina GervasoniPublished in: Obesity (Silver Spring, Md.) (2018)
Improved survival achieved by HIV-infected patients has complicated their medical care, as increasing numbers of comorbidities have led to polypharmacy and a higher risk of drug-drug interactions. Here, evidence is provided that weight-loss drugs should be used with caution in HIV-infected patients treated with lipophilic antiretroviral drugs because of the risk of virologic failure. This is particularly relevant considering that these agents are available on the market as over-the-counter medications, thus escaping the control of the physician.
Keyphrases
- antiretroviral therapy
- hiv infected
- hiv infected patients
- weight loss
- human immunodeficiency virus
- hiv positive
- hiv aids
- bariatric surgery
- roux en y gastric bypass
- gastric bypass
- emergency department
- drug induced
- adverse drug
- health insurance
- type diabetes
- obese patients
- skeletal muscle
- free survival
- metabolic syndrome
- electronic health record
- insulin resistance
- hiv testing
- hepatitis c virus